课题基金 / 基金详情

项目摘要

项目成果

Stephen A Murray的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Orofacial clefting is one of the most common birth defects in humans, affecting approximately 1 in 700 live births. This frequency likely stems from the complexity of craniofacial morphogenesis, which requires precise regulation of gene expression changes, alterations in cell physiology and morphogenic movements. Although an increasing number of genes have been linked to cleft lip and cleft palate, the mechanisms governing orofacial malformations remain unclear. The overall objective of this project is to expand our understanding of the genetic basis of orofacial clefting through the use of a novel mouse model of cleft palate. The ENU-induced clfp4 mouse harbors a recessive mutation causing cleft secondary palate, omphalocele and skeletal malformations with high penetrance. While simultaneous presentation of orofacial clefting and body wall defects is observed in human syndromes, there are few mouse models that recapitulate these phenotypes. Preliminary mapping data places the mutation at the distal end of Chromosome 10, a region where this combination of phenotypes has not been reported. Thus, clfp4 likely represents a new model of craniofacial/body wall birth defects. Although preliminary phenotypic analysis has revealed that cleft palate in this mutant results from a failure of palate shelf elevation, efficient design and interpretation of more detailed experiments, such as marker analysis, would be greatly facilitated by identification of the clfp4 causative gene. To develop this unique model of cleft palate and to elucidate the mechanism underlying the phenotype, we propose to identify the gene that underlies the cflp4 mutation through high-resolution genetic mapping and targeted re-sequencing, and perform basic phenotypic analysis to begin to understand the mechanistic basis of the defect. This work will improve our understanding of the molecular networks that regulate palatogenesis, providing a foundation for the development of new methods for the diagnosis, prevention and treatment of cleft palate and other craniofacial disorders. PUBLIC HEALTH RELEVANCE: Orofacial clefting is one of the most common birth defects in humans, affecting 1 in 700 live births. The total health care costs for surgical repair and post-operative therapies is staggering, and the disfigurement of such disorders often have devastating social and psychological consequences for the affected individual. This proposal will expand our understanding of the etiology of orofacial clefting using a novel mouse model of cleft palate and craniofacial malformations, providing a foundation for the development of new methods for the diagnosis, prevention and treatment of cleft palate and other craniofacial disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical Mouse Model Core
  • 批准号:
    10668764
  • 项目类别:
  • 资助金额:
    $66.97万
  • 财政年份:
    2023
  • 负责人:
    Stephen A Murray
  • 依托单位:
Disease Modeling Unit
  • 批准号:
    10251358
  • 项目类别:
  • 资助金额:
    $124.96万
  • 财政年份:
    2020
  • 负责人:
    Stephen A Murray
  • 依托单位:
Disease Modeling Unit
  • 批准号:
    10469586
  • 项目类别:
  • 资助金额:
    $108.39万
  • 财政年份:
    2020
  • 负责人:
    Stephen A Murray
  • 依托单位:
Animal Model Production Section
  • 批准号:
    10450129
  • 项目类别:
  • 资助金额:
    $4.43万
  • 财政年份:
    2018
  • 负责人:
    Stephen A Murray
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: